S&P 500   2,979.30 (+0.44%)
DOW   26,909.13 (+0.45%)
QQQ   192.15 (+0.55%)
AAPL   236.82 (+0.40%)
FB   185.52 (+1.22%)
MSFT   140.55 (+0.72%)
GOOGL   1,225.03 (+0.60%)
AMZN   1,748.71 (+0.71%)
CGC   19.65 (+4.19%)
NVDA   192.32 (+3.10%)
MU   45.35 (+1.09%)
BABA   174.40 (+1.89%)
GE   8.62 (-1.15%)
TSLA   255.18 (-0.69%)
AMD   30.47 (-0.20%)
T   37.52 (+0.13%)
F   8.81 (-0.11%)
ACB   3.66 (+4.28%)
PRI   121.74 (+0.22%)
NFLX   284.69 (-0.29%)
GILD   64.72 (+0.33%)
DIS   129.58 (-0.09%)
S&P 500   2,979.30 (+0.44%)
DOW   26,909.13 (+0.45%)
QQQ   192.15 (+0.55%)
AAPL   236.82 (+0.40%)
FB   185.52 (+1.22%)
MSFT   140.55 (+0.72%)
GOOGL   1,225.03 (+0.60%)
AMZN   1,748.71 (+0.71%)
CGC   19.65 (+4.19%)
NVDA   192.32 (+3.10%)
MU   45.35 (+1.09%)
BABA   174.40 (+1.89%)
GE   8.62 (-1.15%)
TSLA   255.18 (-0.69%)
AMD   30.47 (-0.20%)
T   37.52 (+0.13%)
F   8.81 (-0.11%)
ACB   3.66 (+4.28%)
PRI   121.74 (+0.22%)
NFLX   284.69 (-0.29%)
GILD   64.72 (+0.33%)
DIS   129.58 (-0.09%)
Log in

NeoGenomics Stock Price, News & Analysis (NASDAQ:NEO)

$19.88
+0.18 (+0.91 %)
(As of 10/15/2019 09:48 AM ET)
Today's Range
$19.71
Now: $19.88
$19.94
50-Day Range
$18.95
MA: $21.77
$24.98
52-Week Range
$11.05
Now: $19.88
$26.89
Volume12,606 shs
Average Volume976,955 shs
Market Capitalization$2.06 billion
P/E Ratio152.92
Dividend YieldN/A
Beta0.92
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories. Read More…

Industry, Sector and Symbol

Industry Testing laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NEO
CUSIPN/A
Phone239-768-0600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$276.74 million
Cash Flow$0.33 per share
Book Value$3.43 per share

Profitability

Net Income$2.64 million

Miscellaneous

Employees1,500
Market Cap$2.06 billion
Next Earnings Date10/29/2019 (Confirmed)
OptionableOptionable

Receive NEO News and Ratings via Email

Sign-up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.


NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) posted its quarterly earnings data on Tuesday, July, 30th. The medical research company reported $0.07 EPS for the quarter, topping the Zacks' consensus estimate of $0.05 by $0.02. The medical research company earned $101.71 million during the quarter, compared to the consensus estimate of $97.32 million. NeoGenomics had a net margin of 0.57% and a return on equity of 4.97%. The company's quarterly revenue was up 50.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.05 EPS. View NeoGenomics' Earnings History.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for NeoGenomics.

How can I listen to NeoGenomics' earnings call?

NeoGenomics will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics issued an update on its FY 2019 earnings guidance on Tuesday, July, 30th. The company provided earnings per share guidance of $0.23-0.27 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.26. The company issued revenue guidance of $388-402 million, compared to the consensus revenue estimate of $393.32 million.

What price target have analysts set for NEO?

7 brokers have issued 12 month target prices for NeoGenomics' stock. Their forecasts range from $15.00 to $30.00. On average, they anticipate NeoGenomics' stock price to reach $24.57 in the next year. This suggests a possible upside of 23.6% from the stock's current price. View Analyst Price Targets for NeoGenomics.

What is the consensus analysts' recommendation for NeoGenomics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.

Has NeoGenomics been receiving favorable news coverage?

Headlines about NEO stock have been trending very negative on Tuesday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NeoGenomics earned a news impact score of -3.8 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for NeoGenomics.

Are investors shorting NeoGenomics?

NeoGenomics saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 5,500,000 shares, an increase of 13.2% from the August 30th total of 4,860,000 shares. Based on an average daily trading volume, of 863,900 shares, the days-to-cover ratio is presently 6.4 days. Currently, 5.6% of the shares of the stock are short sold. View NeoGenomics' Current Options Chain.

Who are some of NeoGenomics' key competitors?

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Netflix (NFLX), Amarin (AMRN), Exelixis (EXEL), Intel (INTC) and AT&T (T).

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the folowing people:
  • Mr. Douglas M. VanOort, Chairman & CEO (Age 64)
  • Ms. Sharon A. Virag, Chief Financial Officer (Age 52)
  • Dr. Lawrence M. Weiss M.D., Chief Scientific Officer (Age 62)
  • Mr. William Bishop Bonello, Chief Strategy & Corp. Devel. Officer and Director of Investor Relations (Age 54)
  • Mr. George A. Cardoza, Pres of Pharma Services Division (Age 57)

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.08%) and Juncture Wealth Strategies LLC (0.01%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View Institutional Ownership Trends for NeoGenomics.

Which institutional investors are buying NeoGenomics stock?

NEO stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue and Juncture Wealth Strategies LLC. View Insider Buying and Selling for NeoGenomics.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $19.88.

How big of a company is NeoGenomics?

NeoGenomics has a market capitalization of $2.06 billion and generates $276.74 million in revenue each year. The medical research company earns $2.64 million in net income (profit) each year or $0.13 on an earnings per share basis. NeoGenomics employs 1,500 workers across the globe.View Additional Information About NeoGenomics.

What is NeoGenomics' official website?

The official website for NeoGenomics is http://www.neogenomics.com/.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]


MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  358 (Vote Outperform)
Underperform Votes:  245 (Vote Underperform)
Total Votes:  603
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe NEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Featured Article: Moving Average (MA)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel